---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006444"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:01:49.378887+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise

## Summary
- Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.
- Romp is CEO of Secura Bio, previously EVP Commercial at Seagen (sold to Pfizer), with 25+ years oncology experience.
- He will receive $50k annual cash retainer, $100k annual equity award, and pro-rated grant of 215 restricted shares vesting by 2026 annual meeting or April 30.
- Company notes preparation for potential approval and launch of gedatolisib later this year (HR+/HER2- advanced breast cancer).
- Romp qualifies as independent under Nasdaq and SEC rules; no committee assignments yet.

## SEC filing metadata
- accession: 0001493152-26-006444
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/0001493152-26-006444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006444
- JSON: https://secwatch.observer/filing/0001493152-26-006444.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.